Terns Pharmaceuticals Inc. (TERN) Begins Dosing in Phase 1 Clinical Trial of TERN-501

Go back to Terns Pharmaceuticals Inc. (TERN) Begins Dosing in Phase 1 Clinical Trial of TERN-501

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH

March 22, 2021 7:35 AM EDT

-TERN-501 is designed to have high metabolic stability, enhanced liver distribution and high selectivity for THR--

-Top-line data expected in the second half of 2021-

FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced the initiation of dosing in a Phase 1 clinical trial evaluating... More